Fibrinolysis and risk of coronary artery disease

Fibrinolysis

Volumn 10, Issue 3, 1996, Pages 127-136

  Juhan Vague, I ^a   Alessi, M C ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; METFORMIN; NICOTINIC ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; REVIEW;

EID: 0029931647     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80023-3     Document Type: Review

References (176)

1. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischémic death. N Engl J Med 1984; 310: 1137-40.
2. Rokitansky K. In: A manual of pathological anatomy. Day GE, trans. London, Sydenham Society 1852: pp 271-73.
3. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 1946; 58: 207-12.
4. Thompson WD, Smith EB. Atherosclerosis and the coagulation system. J Pathol 1989; 159: 97-106.
5. Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-75.
6. Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaphan KK. Identification and distribution of fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis. Arteriosclerosis 1989; 9: 109-21.
7. Naito M, Funaki C, Hayashi T et al. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis 1992; 96: 227-34.
8. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
9. Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis 1994; (suppl. 1) 8 : 269-76.
10. Reilly CF, Fujita T, Hutzelmann JE, Mayer EJ, Shebuski RJ. Plasminogen activator inhibitor 1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation 1991; 84: 287-92.
11. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor 1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemostas 1992; 68: 60-3.
12. Biemond BJ, Levi M, Coronel R, Janse MJ, Ten Gate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effect of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
13. Charlton PA, Faint RW, Bent F et al. A series of low molecular weight inhibitors of plasminogen activator inhibitor (PAI-1) increase fibrinolysis and protect against thrombus formation in the rat. Thromb Haemostas 1995; (abstract 404) 73: 1005.
14. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the PAI-1 gene. Nature 1990; 346: 74-6.
15. Carmeliet P, Bouche A, Schoonjans L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
16. Carmeliet P, Bouche A, De Clercq C et al. Biological effects of disruption of the tissue-type plasminogen activator, urokinase type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann N Y Acad Sci 1995; 748: 367-82.
17. Carmeliet P, Stassen JM, Schoojans L et al. Plasminogen activator inhibitor 1 gene deficient mice. II. Effects on hemostasis thrombosis and thrombolysis. J Clin Invest 1993; 92: 2756-60.
18. Saksela O, Rifkin DB. Cell associated plasminogen activation: Regulation and physiological function. Ann Rev Cell Biol 1988; 4: 93-126.
19. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992; (suppl III) 85: III-43. III-46.
20. Clowes AW, Clowes MM, YPT A, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue type plasminogen activator during migration in injured rat carotid artery. Circulation Res 1990; 67: 61-7.
21. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after ballon catheter injury. Arterioscler Thromb 1993; 13: 1218-26.
22. Vassalli JD. The urokinase receptor. Fibrinolysis 1994; (suppl.1) 8: 172-81.
23. Reuning U, Bang NU. Regulation of the urokinase type plasminogen activator receptor on vascular smooth muscle cell is under the control of thrombin and other mitogens. Arterioscler Thromb 1992; 12: 1161-70.
24. Herbert JM, Lamarche I, Prabonnaud V, Dol F, Gauthier T. Tissue type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 1994; 269: 3076-80.
25. Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg 1994; 19: 865-872.
26. Sawa H, Fujii S, Sobel BE. Augmented arterial wall expression of type 1 plasminogen activator inhibitor induced by thrombosis. Arterioscler Thromb 1992; 12: 1507-15.
27. Schneiderman J, Sawdey MS, Keeton MR et al Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
28. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor 1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemostas 1994; 72: 44-53.
29. Lupu F, Bergonzelli GE, Heim DA et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and athrosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
30. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar W, Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
31. Underwood MJ, De Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res 1993; 27: 882-5.
32. Padro T, Emeis JJ, Steins M, Schmid KW-Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessed wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995; 15: 893-902.
33. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody based enzyme linked immunosorbent assay. Blood. 1988; 71: 220-25.
34. Booth NA, Simpson AJ, Croll A, Bennett B, Mac Gregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988; 70: 327-33.
35. Junan-Vague I, Alessi MC, Fossat C, Declerck PJ, Kruithof EKO. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemostas 1987; 58; 1096.
36. Rijken DC, Juhan-Vague I, Collen D. Complexes between extrinsic plasminogen activator and proteinase inhibitors in human plasma identified with an immunoradiometric assay. J Lab Clin Med 1983; 101: 285-94.
37. Ranby M, NíGuyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemostas 1989; 61: 409-14.
38. Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Guenoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res 1990; 60: 509-16.
39. Haverkate F, Thrombosis and Disabilities. In: Baya C, ed. Adv Med Biol, Amsterdam: IOS Press, 1994; pp 81-103.
40. Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris: relation to gender, age and acute-phase reaction. Thromb Haemostas 1995; 73: 561-67.
41. Juhan-Vague I, Alessi MC, Joly P et al. Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989; 9: 362-67.
42. Nicoloso G, Hauert J, Kruithof EKO, van Melle G, Bachmann F. Fibrinolysis in normal subjects: comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemostas 1988; 59: 299-303.
43. Kruithof EKO. I- Plasminogen activator inhibitor activity assay. II- Plasminogen activator inhibitor 1 antigen. In: Jespersen J, Bertina RM, Haverkate F eds. ECAT assay procedures. A manual of Laboratory techniques. Dordrecht: Kluwer Academic Publishers. 1992: 147-50 (I); 151-53 (II).
44. Hadjez JM, Combe S, Horellou MH et al. Heterogeneous mechanisms responsible for reduced fibrinolytic capacity in patients with a history of venous thrombosis. Fibrinolysis 1994; 8: 87-95.
45. Pedersen OD, Gram J, Jespersen J. Plasminogen activator inhibitor type 1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemostas 1995; 73: 835-40.
46. Meade TW, Howarth DJ, Cooper J, Mac Callum PK, Stirling Y. Fibrinolytic activity and arterial disease. Lancet 1994; 343: 1442.
47. Jansson JH, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem 1989; 35: 1544-50.
48. Nguyen ND, Ghaddar H, Stinson V, Chambless LE, Wu KK. ARIC hemostasis study. Intraindividual variability and reliability of hemostatic factors. Thromb Haemostas 1995; 73: 256-60.
49. Prinz MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Amer Heart J 1991; 122: 545-51.
50. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemostas 1993; 70: 138-43.
51. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: An update. Fibrinolysis 1994; (suppl.1) 8: 253-62.
52. Rocha E, Paramo JA. The relationship between impaired fibrinolysis and coronary heart disease. A role for PAI-1. Fibrinolysis 1994; 8: 294-303.
53. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the North wick Park Heart Study. Lancet 1993; 342: 1076-79
54. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-61.
55. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7 year follow up. Circulation 1993; 88: 2030-34
56. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41
57. Van de Loo JCW. Haverkate F, Thompson SG. Hemostatic factors and the risk of myocardial infarction. N Engl J Med 1995; 332: 389-90.
58. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet. 1993; 341: 1165-68.
59. Hamsten A, De Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; II: 3-9.
60. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial infarction. Acta Med Scand 1987; 221: 149-53.
61. Gram J, Jespersen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction. Thromb Haemostas 1987; 57: 137-39.
62. Cortellaro M, Cofrancesco E, Boschetti C et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993; 13: 1412-17.
63. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Med J 1991; 66: 351-55.
64. Cimmiello C. Tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 342: 48-9.
65. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990; 11: 525-28.
66. Paramo JA, Colucci M, Collen D, van Der Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 575-76
67. Aznar J, Estelles A, Tormo G et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-41.
68. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93.
69. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentration. J Am Coll Cardiol 1987; 9: 263-68.
70. Huber K, Resch I, Stefenelli T, Lang I, Probst P, Kaindl F, Binder BR. Plasminogen activator inhibitor 1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemostas 1990; 63: 336-39.
71. Verbeugt FWA, Ten Gate JW, Sturk A et al. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 1987; 59: 1075-79.
72. Sakata K, Kurata C, Taguchi T et al. Clinical significance of plasminogen activator inhibitor activity in patients with exercise-induced ischemia. Am Heart J 1990; 120: 831-38.
73. Thompson SG, Van de Loo JCW. ECAT Angina Pectoris Study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
74. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Circulation 1995; 91: 284-90.
75. Grobbee DE, Hoes AW, Koudstaal PJ, Hofman A, Bots ML. Carotid intima-media thickness predicts myocardial infarction and stroke. The Rotterdam Study. Circulation 1996 (abstract); 93: 630.
76. Huber K, Jorg M, Probst P Schuster E, Lang I, Kaindl F, Binder BR. A decrease in plasminogen activator inhibitor I activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemostas 1992; 67: 209-13.
77. Sakata K, Miura F, Sugino H et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1-6.
78. Kirschstein W, Simianer S, Dempfle CE, Keller H, Stegaru B, Rentrop P, Heene DL. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty. Thromb Haemostas 1989; 62: 772-75.
79. Barbash GI, Hod H, Roth A et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery, thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-35.
80. Sane DC, Stump DC, Sigmon KN et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemostas 1991; 65: 275-79.
81. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction. A role for plasminogen activator inhibitor ? Br Heart J 1993, 70, 530-36.
82. Lucore CL, Sobel BE. Interactions of tissue type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988; 77: 660-69.
83. Andreotti F, Roncaglione MC, Hackett DR et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor 1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990; 16: 1553-60.
84. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
85. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb. 1993; 13: 1865-73.
86. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-49.
87. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1 : implications for vascular disease in hyperinsulinemic states. Proc Nat Acad Sci USA 1991; 88: 9959-63.
88. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
89. Reaven G.M. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
90. Zimmet P. The epidemiology of diabetes mellitus and related conditions. In: The diabetes annual 6. Alberti KGMM, Krall CP, eds, Amsterdam: Elsevier, 1991, 1-19
91. Eschwege E, Richard JL, Thibult N, DucimetiËre P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985; 15: 41-6.
92. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9-year follow-up of the Helsinki Policemen Study population. Acta Med Scand 1985; 701 (suppl.): 38-52.
93. Welborn T.A., Wearne K. Coronary heart disease and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-60.
94. Lindahl B, Asplund K, Hallmans G. High serum insulin, insulin resistance and their associations with cardiovascular risk factors. The Northern Sweden MONICA population study. J Int Med 1993; 234: 263-70.
95. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22.
96. Vague P, Juhan-Vague I, Aillaud MF et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-53.
97. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-09.
98. Hamsten A, Karpe F, Bavenholm P, Silveira A. Interactions amongst insulin, lipoproteins and haemostatic function relevant to coronary heart disease. J Int Med 1994; 236: 75-88.
99. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
100. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemostas 1989; 61: 370-73.
101. Mahmoud R, Raccah D, Alessi MC, Aillaud MF, Juhan-Vague I, Vague P. Fibrinolysis in insulin dependent diabetic patients with or without nephropathy. Fibrinolysis 1992; 6: 105-09.
102. Garcia Frade LJ, de la Galle H, Torade MC, Lara JI, Cuellar L, Garcia Avello A. Hypofibrinolysis associated with vasculopathy in non-insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-9.
103. Gray RP, David L, Patterson H, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb 1993; 13: 415-20.
104. Gray RP, Yudkin JS, Patterson DL. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1993; 69: 228-32.
105. Gray RP, Vidya MA, Patterson DLH, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemostas 1995; 73: 261-7.
106. Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsj Sweden. J Clin Epidemiol 1989; 42: 719-23.
107. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47: 513-24.
108. Bavenholm P, Proudler A, Silveira A, Crook D, Blombäck M, de Faire U, Hamsten A. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb Haemostas 1995; 73: 568-75.
109. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Medicine 1993; 10: 27-32.
110. Nagi DK, Hendra TJ, Ryle AJ et al. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non insulin dependent) diabetic subjects. Diabetologia 1990; 33: 532-37.
111. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemostas 1987; 57: 326-28.
112. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with Metformin reduces both blood pressure and metabolic risk factors. J Int Med 1991; 229: 181-87.
113. Sundell IB, Dahlgren S, Ranby M, Lundin E, Stealing R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989; 3: 51-53.
114. Mehrabian M, Peter JB, Barnard RJ, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990; 84: 25-32.
115. Huisveld LA, Leen R, VdKooy K et al. Body composition and weight reduction in relation to antigen and activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis 1990; 4: 184-85.
116. Speiser W, Langer W, Pschaick A et al. Increased blood fibrinolytic activity after physical exercise: Comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb Res 1988; 51: 543-55.
117. Estelles A, Aznar J, Tormo G, Sapena P, Tormo V, Espana F. Influence of a rehabilitation sports program on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 1989; 55: 203-12.
118. Gris JC, Schved JF, Aguilar-Martinez P, Arnaud A, Sanchez N. Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 1990; 4: 97-8.
119. Shaukat N, Douglas JT, Bennett JL, de Bono DP. Can physical activity explain the differences in insulin levels and fibrinolytic activity between young indo-origin and european relatives of patients with coronary artery disease ? Fibrinolysis 1995; 9: 55-63.
120. Andersen P, Smith P, Seljeflot I, Brataker S, Arnasen H. Effects of Gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemostas 1990; 63: 174-77.
121. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by Niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995; 92: 767-72.
122. Lundgren CH, Brown NA, Nordt TK, Sobel BE, Fujii S. Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-10.
123. Samad F, Yamamoto K, Loskutoff DJ Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. J Clin Invest 1996; 97: 37-46.
124. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-94.
125. Kooistra T, Bosma PJ, Töns HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1 : biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989; 62: 723-28.
126. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I. Plasminogen activator inhibitor 1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest 1993; 91: 2185-93.
127. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type 1 in endothelial cells. Diabetes 1992; 41: 890-95.
128. Alessi MC, Anfosso F, Henry M, Peiretti F, Nalbone G, JuhanVague I. Up-regulation of PAI-1 synthesis by insulin and proinsulin in Hep G2 cells but not in endothelial cells. Fibrinolysis 1995; 9: 237-42.
129. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type 1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 1994; 89: 321-30.
130. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type 1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-70.
131. Anfosso F, Alessi MC, Nalbone G, Chomiki N, Henry M, Juhan-Vague I. Up-regulated expression of plasminogen activator inhibitor -1 in Hep-G2 cells: Interrelationship between insulin and insulin-like growth factor-1. Thromb Haemostas 995; 73: 268-74.
132. Padayatty SJ, Orme S, Zenobi PD, Stickland MH, Belchetz PE, Grant PJ. The effects of insulin-like growth factor-1 on plasminogen activator inhibitor-! synthesis and secretion: Results from in vitro and in vivo studies. Thromb Haemostas 1993; 70: 1009-13.
133. Sawdey S, Loskutoff DJ. Regulation of murine type 1 plasminogen activity inhibitor (PAI-1) gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor a and transforming growth factor b. J Clin Invest 1991; 88: 1346-53.
134. Fujii S, Sawa H, Saffitz JE, Lucore CL, Sobel BE. Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo. Circulation 1992; 86: 2000-10.
135. Wojta J, Gallicchio M, Zoellner H et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemostas 1993; 70: 469-74.
136. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-73
137. Mussoni L, Mannucci L, Sirtori M et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-25.
138. Tremoli E, Camera M, Maderna P et al. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to nature and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993; 13: 338-46.
139. Sironi L, Mussoni L, Prati L et al. Plasminogen activator inhibitor type 1 synthesis and mRNA expression in Hep G2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996; 16: 89-96.
140. Latron Y, Chautan M, Anfosso F et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-29.
141. Chautan M, Latron Y, Anfosso F et al. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothalial cells. J Lipid Res 1993; 34: 101-10.
142. Etingin O, Hajjar D, Hajjar K, Harpel P, Nachman R. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459-65.
143. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-28.
144. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994; 14: 1264-71.
145. Caron P, Bennet A, Camare R, Louvet JP, Boneu B, Sie P. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989; 38: 1010-15.
146. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in NIDDM. Ann Med (in press).
147. Folsom AR, Qamhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1) factor VII, and other hemostatic factors in moderately over weight adults. Arterioscler Thromb 1993; 13: 162-69.
148. Vukovich T, Proidl S, Knöbl P, Teufelsbauer H, Schnack C, Schernthaner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor 1 in type 2 diabetic patients. Thromb Haemostas 1992; 68: 253-56.
149. Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993; 71: 405-15.
150. Alessi MC, Parrot G, Guenoun E, Scelles V, Vague P, JuhanVague I. Relation between plasma PAI activity and Adipsin levels. Thromb Haemostas 1995; 74: 1200-02.
151. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor a: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
152. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-09.
153. Ernst E. Plasma fibrinogen. an independent cardiovascular risk factor. J Int Med 1990; 227: 365.
154. Meade TW, Brozovic M, Haines AP et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533
155. Juhan-Vague I, Aillaud MF, De Cock F et al. The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant protein. In: Davidson JF, Donati MB, Coccheri S, eds. Progress in fibrinolysis Vol III. New York. Churchill Livingstone 1985: 146-49.
156. Kluft C, Verheijen JH, Jie AFH et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-10.
157. Aillaud MF, Juhan-Vague I, Alessi MC et al. Increased levels of plasminogen activator inhibitor (PAI-1) in the post operative period. No relationship with increased cortisol. Thromb Haemostas 1985; 54: 466-68.
158. Lowe GDO, Rumley A, Lee AJ, Crilly A, Madhok R, Tunstall-Pedoe H. Correlation of plasma fibrinogen, plasminogen activator inhibitor and red cell aggregation with interleukin-6 levels in a population study. Thromb Haemostas 1993, 69 (abstract): 763.
159. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. Von Willebrand factor is an acute phase-reactant in man. Thromb Res 1989; 53: 387-94.
160. De Maat MPM, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996 (in press).
161. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor 1 in cultured endothelial cells. A potential link between the reninangiotensin system and thrombosis. J. Clin. Invest. 1995; 95: 995-1001.
162. Van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor 1 and tissue type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-68.
163. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-62.
164. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-20.
165. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of Captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
166. Mansfield MW, Strickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in
167. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.
168. Winger KW, Winqvist R, Riccio A et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 1987; 84: 8548-52.
169. Dawson S, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to Interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
170. Eriksson P, Kallin B, vanít Hooft, Bavenholm P, Hamsten A. Allele-speciflc increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-55.
171. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambon JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemostas 1995; 74: 837-41.
172. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42.
173. Mansfied MW, Strickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemostas 1995; 74: 842-47.
174. Bosnia PJ, van den Berg EA, Kooistra T. Human plasminogen activator inhibitor 1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988; 263: 9129-41.
175. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990; 76: 930-37.
176. Brommer EJP, Derkx FHM, Schalekamp MADH, Dooijewaard G, Klaauw MM. Renal and hepatic handling of endogenous tissue-type plasminogen activator and its inhibitor in man. Thromb Haemostas 1988; 59: 404-11.